Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.
Study shows Paris climate agreement has significantly reduced superhot days, but small nations face disproportionate impact ...